Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 296,924 shares, an increase of 417.6% from the July 15th total of 57,363 shares. Currently, 0.6% of the shares of the company are short sold. Based on an average daily volume of 19,111,558 shares, the days-to-cover ratio is currently 0.0 days.
Zhengye Biotechnology Stock Down 1.3%
Shares of NASDAQ:ZYBT traded down $0.02 during mid-day trading on Thursday, reaching $1.53. 158,697 shares of the company traded hands, compared to its average volume of 2,225,819. The company’s 50 day moving average price is $1.23 and its 200-day moving average price is $1.02. The company has a current ratio of 1.14, a quick ratio of 0.82 and a debt-to-equity ratio of 0.03. Zhengye Biotechnology has a 52 week low of $0.62 and a 52 week high of $13.08.
Hedge Funds Weigh In On Zhengye Biotechnology
Several institutional investors have recently bought and sold shares of ZYBT. Citadel Advisors LLC bought a new stake in shares of Zhengye Biotechnology in the 3rd quarter worth about $31,000. Millennium Management LLC bought a new position in Zhengye Biotechnology during the 3rd quarter valued at about $38,000. WINTON GROUP Ltd purchased a new stake in Zhengye Biotechnology in the 3rd quarter worth about $56,000. Geode Capital Management LLC purchased a new stake in Zhengye Biotechnology in the 2nd quarter worth about $174,000. Finally, Invesco Ltd. bought a new stake in Zhengye Biotechnology in the second quarter worth about $220,000.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on ZYBT
About Zhengye Biotechnology
Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.
Featured Stories
- Five stocks we like better than Zhengye Biotechnology
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Zhengye Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhengye Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
